Scientific American3y
Targeting the Toughest Signaling Pathway in Cancer
By the late 1990s, scientists had managed to identify drugs that worked against mutant proteins that function in specific signaling pathways that cancer cells rely on—a step that ushered in a ...
Healio4d
Topical gel shows promise in treating cutaneous events from EGFR inhibitor cancer therapy
A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...
Medscape10y
Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined ...
Business Wire1mon
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
We are proud to have long supported patients with EGFR-mutated lung cancer and look forward to the possibility of bringing another innovative treatment option to this community.” Ken Takeshita ...
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...